CLSA Congratulates Pantheon 2016 Life Sciences Leadership Award Winners and Reports Management Growth
President & CEO
CLSA – California Life Sciences Association
September 15, 2016
Welcoming New Members
Please welcome our newest CLSA members: Akin Gump Strauss Hauer & Feld LLP, AngStrom Biotechnologies, CI Diagnostics, Koniku, NeuCyte, Never Peak, OncoStemyx, Senti Biosciences and TB-SEQ! These great organizations join our 750+ membership portfolio and add significantly to the expertise and resources available in the CLSA network.
Daiichi Sankyo Partnership Day
On September 8th, CLSA hosted another successful partnering day with Daiichi Sankyo, bringing together more than 90 life sciences members from 70+ start-up companies at a networking reception to discuss potential partnership and collaboration opportunities. In addition to the networking receptions, we were also able to facilitate 35 in-person meetings, as well as another eight introductions to meet later this month.
Pantheon 2016 – CLSA Congratulates Our 2016 Life Sciences Leadership Award Winners
The 2016 Life Sciences Leadership Awards will be presented to two of the most renowned innovators in the industry: David Pyott and Scott Morrison. David Pyott, known for transforming a small eye care business into a globally dominant specialty pharmaceutical and medical device company, is both a leader and a success story that inspires and encourages future generations of life science entrepreneurs. Scott Morrison is a life sciences mentor who helped numerous companies excel from start-up, through initial product launch, to global expansion. He has worked on hundreds of public and private financings, and his success greatly impacted the industry’s ability to grow and develop for the last thirty-five years. Please join us in celebrating their accomplishments at Pantheon 2016.
We’re Growing! Welcoming Two Strategic Leaders to CLSA
Heather Shane, Executive Director of CLSI’s CARB-X program
I’d like to congratulate Heather Shane on her appointment to lead the CLSI CARB-X accelerator, which will provide non-dilutive funding, business support and subject matter expertise to companies with innovative antibiotic product candidates. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is the world’s largest public-private partnership focused on tackling one of the greatest modern threats to public health — antibiotic resistance. CARB-X will commit $50 million during the first year, and at least $350 million over five years, toward preclinical research and development with the aim of accelerating antibiotic product development over the next 25 years. CLSI is CLSA’s non-profit partner that supports the foundations of innovation – workforce development, STEM education and entrepreneurship – that have made California home to the world’s most prominent life sciences ecosystem.
Prior to joining CLSI, Heather served as Vice President & Assistant General Counsel at Theravance Biopharma (TBPH), a Bay Area biopharmaceutical company. At TBPH, Heather handled a broad range of corporate, financing, partnering and operational matters, and honed her legal and business skills in the drug discovery and clinical development process, product commercialization and the regulatory and compliance regimes governing these activities. Heather joined TBPH in connection with its 2014 spin-off from Theravance (now known as Innoviva), where she also served as VP & Assistant General Counsel. Before joining Theravance in 2005, Ms. Shane was a corporate associate with Gunderson Dettmer Stough Villeneuve & Hachigian where she represented startups, venture capital and public company clients in a variety of transactions. Heather earned her J.D. from NYU School of Law and her B.A. from the University of California Santa Barbara.
CARB-X grew out of President Obama’s 2015 Combating Antibiotic-Resistant Bacteria (CARB) initiative and will address several goals laid out in the U.S. Federal CARB National Action Plan.
The consortium is led by CARB-X Executive Director and Principal Investigator Kevin Outterson from Boston University School of Law, and currently is comprised of four accelerator sites: The Wellcome Trust; the AMR Centre; MassBio in Cambridge, MA; and CLSI in the San Francisco Bay Area. These sites will provide world-class business support and mentoring services to innovative product developers selected for CARB-X funding.
The executive team includes experts with decades of experience in antibiotic drug development, including John Rex, Senior Vice President at Astra Zeneca and, as of January 1, 2017, Barry Eisenstein, formerly of Cubist and currently at Merck. The National Institutes of Health’s National Institute of Allergy and Infectious Disease (NIAID) will provide in-kind services and technical support to projects in the CARB-X portfolio, and RTI International will provide technical and regulatory support services to product developers and build the computing systems to identify, track and monitor all research programs. The Broad Institute of MIT and Harvard will host the new inter-disciplinary Collaborative Hub for Early Antibiotic Discovery (CHEAD) aimed at accelerating the development of small molecule compounds into clinical therapeutics.
For more information on CARB-X, please visit: http://www.carb-x.org/
We continue to build our team to better serve California’s life sciences ecosystem. As the nation’s largest statewide public policy advocacy and business solutions organization, CLSA is expanding and seeking to fill the following positions:
Visit CLSA’s Career Opportunities center to learn more.
President & CEO
California Life Sciences Association
PS – Have newsworthy items to submit for consideration for our monthly CLSA Bulletin? Feel free to send those tips to Bianca Leveriza, CLSA’s Associate, Marketing & Events (BLeveriza@CALifeSciences.org).